Logo image of EDIT

EDITAS MEDICINE INC (EDIT) Stock Fundamental Analysis

NASDAQ:EDIT - Nasdaq - US28106W1036 - Common Stock - Currency: USD

1.92  -0.14 (-6.8%)

After market: 1.98 +0.06 (+3.13%)

Fundamental Rating

3

Taking everything into account, EDIT scores 3 out of 10 in our fundamental rating. EDIT was compared to 571 industry peers in the Biotechnology industry. EDIT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EDIT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EDIT has reported negative net income.
In the past year EDIT has reported a negative cash flow from operations.
EDIT had negative earnings in each of the past 5 years.
In the past 5 years EDIT always reported negative operating cash flow.
EDIT Yearly Net Income VS EBIT VS OCF VS FCFEDIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

EDIT has a Return On Assets of -64.28%. This is in the lower half of the industry: EDIT underperforms 61.81% of its industry peers.
The Return On Equity of EDIT (-119.89%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.28%
ROE -119.89%
ROIC N/A
ROA(3y)-33.99%
ROA(5y)-29.7%
ROE(3y)-46.59%
ROE(5y)-44.04%
ROIC(3y)N/A
ROIC(5y)N/A
EDIT Yearly ROA, ROE, ROICEDIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

EDIT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDIT Yearly Profit, Operating, Gross MarginsEDIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EDIT has more shares outstanding
Compared to 5 years ago, EDIT has more shares outstanding
There is no outstanding debt for EDIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EDIT Yearly Shares OutstandingEDIT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
EDIT Yearly Total Debt VS Total AssetsEDIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

EDIT has an Altman-Z score of -6.80. This is a bad value and indicates that EDIT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.80, EDIT is not doing good in the industry: 68.21% of the companies in the same industry are doing better.
EDIT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.8
ROIC/WACCN/A
WACC9.52%
EDIT Yearly LT Debt VS Equity VS FCFEDIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.75 indicates that EDIT has no problem at all paying its short term obligations.
EDIT has a Current ratio of 3.75. This is comparable to the rest of the industry: EDIT outperforms 44.23% of its industry peers.
EDIT has a Quick Ratio of 3.75. This indicates that EDIT is financially healthy and has no problem in meeting its short term obligations.
EDIT has a Quick ratio of 3.75. This is comparable to the rest of the industry: EDIT outperforms 45.65% of its industry peers.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.75
EDIT Yearly Current Assets VS Current LiabilitesEDIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.19% over the past year.
EDIT shows a strong growth in Revenue. In the last year, the Revenue has grown by 150.84%.
Measured over the past years, EDIT shows a quite strong growth in Revenue. The Revenue has been growing by 19.59% on average per year.
EPS 1Y (TTM)5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.36%
Revenue 1Y (TTM)150.84%
Revenue growth 3Y-4.86%
Revenue growth 5Y19.59%
Sales Q2Q%-98.86%

3.2 Future

EDIT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.09% yearly.
EDIT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.02% yearly.
EPS Next Y-33.3%
EPS Next 2Y12.87%
EPS Next 3Y10.11%
EPS Next 5Y5.09%
Revenue Next Year14.24%
Revenue Next 2Y-45.67%
Revenue Next 3Y-31.04%
Revenue Next 5Y10.02%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EDIT Yearly Revenue VS EstimatesEDIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
EDIT Yearly EPS VS EstimatesEDIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EDIT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EDIT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDIT Price Earnings VS Forward Price EarningsEDIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDIT Per share dataEDIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.87%
EPS Next 3Y10.11%

More info and screens

0

5. Dividend

5.1 Amount

EDIT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDITAS MEDICINE INC

NASDAQ:EDIT (2/21/2025, 8:15:05 PM)

After market: 1.98 +0.06 (+3.13%)

1.92

-0.14 (-6.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)02-26 2025-02-26/amc
Inst Owners71.56%
Inst Owner Change-7.65%
Ins Owners0.28%
Ins Owner Change-0.03%
Market Cap158.50M
Analysts70
Price Target4.53 (135.94%)
Short Float %20.77%
Short Ratio6.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.37%
Min EPS beat(2)-14.27%
Max EPS beat(2)1.53%
EPS beat(4)2
Avg EPS beat(4)8.39%
Min EPS beat(4)-14.27%
Max EPS beat(4)58.41%
EPS beat(8)5
Avg EPS beat(8)8.8%
EPS beat(12)9
Avg EPS beat(12)9.31%
EPS beat(16)11
Avg EPS beat(16)6.21%
Revenue beat(2)0
Avg Revenue beat(2)-93.72%
Min Revenue beat(2)-97.34%
Max Revenue beat(2)-90.11%
Revenue beat(4)1
Avg Revenue beat(4)91.95%
Min Revenue beat(4)-97.34%
Max Revenue beat(4)641.15%
Revenue beat(8)4
Avg Revenue beat(8)88.32%
Revenue beat(12)7
Avg Revenue beat(12)75.85%
Revenue beat(16)10
Avg Revenue beat(16)59.51%
PT rev (1m)4.02%
PT rev (3m)-67%
EPS NQ rev (1m)18.33%
EPS NQ rev (3m)23.54%
EPS NY rev (1m)2.82%
EPS NY rev (3m)2.67%
Revenue NQ rev (1m)4.87%
Revenue NQ rev (3m)12.1%
Revenue NY rev (1m)-4.89%
Revenue NY rev (3m)-6.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.57
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-2.56
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)-2.32
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0.75
BVpS2.13
TBVpS2.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.28%
ROE -119.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.99%
ROA(5y)-29.7%
ROE(3y)-46.59%
ROE(5y)-44.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 162.85%
Cap/Sales 15.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.75
Quick Ratio 3.75
Altman-Z -6.8
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)100.28%
Cap/Depr(5y)139.93%
Cap/Sales(3y)19.4%
Cap/Sales(5y)19.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.36%
EPS Next Y-33.3%
EPS Next 2Y12.87%
EPS Next 3Y10.11%
EPS Next 5Y5.09%
Revenue 1Y (TTM)150.84%
Revenue growth 3Y-4.86%
Revenue growth 5Y19.59%
Sales Q2Q%-98.86%
Revenue Next Year14.24%
Revenue Next 2Y-45.67%
Revenue Next 3Y-31.04%
Revenue Next 5Y10.02%
EBIT growth 1Y-9.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.46%
EBIT Next 3Y11.1%
EBIT Next 5YN/A
FCF growth 1Y-8.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.13%
OCF growth 3YN/A
OCF growth 5YN/A